Micropulse Transscleral Diode Laser Cyclophotocoagulation (MP-TSCPC) as a Treatment Modality for Glaucoma Patients
Study Details
Study Description
Brief Summary
The study objective was to evaluate the efficacy and safety of transscleral cyclophotocoagulation (TSCPC) using micropulse diode laser treatment in patients with various types of glaucoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Evaluation of the efficacy and safety of a new form of transscleral cyclophotocoagulation (TSCPC) using micropulse diode laser treatment in patients with various types of glaucoma.
In this study, 810 nm infrared diode laser radiation in the micro- pulse mode was used in conjunction with a G probe (IRIDEX Medical Instruments, Mountain View, CA, USA).
The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser set on micro- pulse mode, delivered over 100-200 seconds (envelope of micropulses) depending on severity of the case and other patient factors. With duty cycle 31.3% (This translates to 0.5 ms "on" time and 1.1 ms "off" time), which allows the tissue to cool down between laser shots, thus greatly reducing thermal damage.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Glaucoma patients Patients were enrolled from outpatient clinic with glaucoma during the period between January 2020 and July 2021 |
Device: Micropulse transscleral cyclophotocoagulation (MP-TSCPC)
patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.
Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively.
|
Outcome Measures
Primary Outcome Measures
- Intraocular pressure (IOP) [Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively]
significant change in IOP in mmHg.
- best corrected visual acuity (BCVA) [Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively]
change in BCVA using snellen's chart
Secondary Outcome Measures
- complication rate. [Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively]
Describing any complications related to the procedure.
- change in number of postoperative glaucoma medications. [Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively]
Number of postoperative glaucoma medications.
- retreatment rate. [Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively]
percentage of patients needing further treatment.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients previously diagnosed with glaucoma if they had uncontrolled Intraocular pressure despite maximal tolerated medical therapy.
-
Patients who are unable to maintain compliance with the prescribed topical medications.
-
Patients who need filtering glaucoma surgery for controlling Intraocular pressure but are not generally fit for the surgery.
-
Patients who refused incisional procedures like subscleral trabeculectomy.
Exclusion Criteria:
-
Patients who were unable to give informed consent.
-
Patients who had undergone previous conventional transscleral diode laser cyclophotocoagulation (TSCPC).
-
Patients with significant scleral thinning defined as thinning of more than one clock hour noticed on scleral transillumination.
-
Patients with ongoing ocular infection or inflammation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Benha University | Banhā | Other | Egypt | 13511 |
Sponsors and Collaborators
- Benha University
Investigators
- Principal Investigator: Gehad H Youssef, Msc, Benha University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MS 9-222